GRK2 is a novel early marker of cardiotoxicity in response to doxorubicin

Abstract

Background: Doxorubicin is among widely used anticancer drugs, but its efficacy is limited by a cumulative dose-dependent cardiotoxicity which can lead to severe heart failure. The current goal of cardio- oncology research is the identification of early markers, molecules which result altered in early stage of cardiotoxic damage, and among different cardiac cell types involved in cardiotoxic response. Recently, GRK2 has been proposed as an early marker of cardiac injury, and its myocardial expression is mirrored by its lymphocytes levels.